| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5703070 | American Journal of Ophthalmology | 2016 | 15 Pages |
Abstract
The results of this small study suggest that blockage of IL-1β using gevokizumab may be beneficial in treating active, noninfectious anterior scleritis and that gevokizumab is well tolerated. Larger randomized trials are warranted to assess the true efficacy of gevokizumab in the treatment of non-necrotizing anterior scleritis.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jared E. Knickelbein, William R. Tucker, Nirali Bhatt, Karen Armbrust, David Valent, Dominic Obiyor, Robert B. Nussenblatt, H. Nida Sen,